News
Hera Fertility launches new financing plans to help couples struggling to conceive
The New York-based digital fertility company works with fertility clinics to help couples access fertility treatment
The US fertility provider Hera Fertility has launched a new financing option for couples struggling with infertility.
The new financing plan, which offers 0% interest rates, would make it easier for couples to build a family during a time when challenging economic times prompt interest rates to rise.
With the rising costs of fertility treatments and healthcare in general, many couples struggle to afford the necessary treatments to help them conceive.
A single IVF cycle — defined as ovarian stimulation, egg retrieval and embryo transfer — can range from US$15,000 to US$30,000, depending on the clinic and the patient’s needs.
Rising interest rates further compound the problem, making it even more difficult for consumers to borrow the money they need to cover these expenses.
“We understand that infertility can be a stressful and emotional journey, and we want to do everything we can to help make it easier for our patients,” explains Thiv Paramsothy, CEO of Hera Fertility.
“By offering 0% APR financing, we hope to remove one of the financial barriers that can prevent couples from seeking the care they need, particularly during this time of economic uncertainty.”
The new financing plan will be available to all patients who qualify for Hera Fertility’s services, including IVF, IUI and egg freezing.
Patients can choose from a range of financing options to fit their budget and timeline, with repayment plans ranging from 12 to 18 months.
“We believe that everyone deserves the chance to build a family, regardless of their financial situation,” Paramsothy adds.
“Our 0% APR financing option is just one way that we’re working to make fertility treatments more accessible and affordable for everyone, particularly during these uncertain economic times.”
Hera Fertility, a New York-based digital fertility company, works with fertility clinics and other family-building companies to make fertility more affordable.
The company provides fertility financing and family-building care and helps couples compare offers from multiple lenders to get the best rate.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Hormonal health3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Diagnosis2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






